Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is demonstrating significant potential in the oncology sector with its pipeline candidate BDTX-1535, which has shown a 36% objective response rate (ORR) among evaluable patients with challenging EGFR mutations, improving to 42% when excluding those without on-target resistance mutations. The company's development focus on non-classical EGFR non-small cell lung cancer (NSCLC) positions it well, as this patient population is underserved by existing therapies, suggesting a substantial market opportunity. Additionally, with 74% of patients remaining on treatment as of the latest data cut, there is a positive indication for the drug's durability and further development, with data updates expected in 2025 to continue validating the favorable outlook.

Bears say

Black Diamond Therapeutics Inc faces significant risks associated with its drug candidate BDTX-1535, including potential negative efficacy data that could adversely impact its market viability. The company is also grappling with long-term dilution risks and has adjusted its expense assumptions and commercialization timeline, leading to a downward revision of its target price. Financial projections indicate a continued trend of net losses, with an anticipated net loss of $1.32 per share for the full year of 2025, reflecting ongoing operational challenges.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.